David R. Plowchalk

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

Odette A. Fahmi, Susan Hurst, David R. Plowchalk et al. · Drug Metabolism and Disposition · 2009 · 210 citations

An EP2 receptor-selective prostaglandin E₂agonist induces bone healing

Vishwas Paralkar, Fran Borovečki, H.Z. Ke et al. · Proceedings of the National Academy of Sciences · 2003 · 185 citations · Full text

Prostaglandin E2, Molecular Physiology, Sclerostin +11

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

Christie M. Ballantyne, Joel Neutel, Anne Cropp et al. · The American Journal of Cardiology · 2015 · 168 citations · Full text

Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide

David R. Plowchalk, Donald R. Mattison · Toxicology and Applied Pharmacology · 1991 · 118 citations

Medicine, Gynecology, Toxicology +7

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

Hannah M. Jones, Iain Gardner, Wendy T. Collard et al. · Clinical Pharmacokinetics · 2011 · 111 citations

Physiologically Based Pharmacokinetics, Pharmacokinetic Modelling, Pharmacodynamics +10